Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
The restructured biotech’s new lead project enters phase 1.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
The private biotech adds another asset to J&J’s prostate cancer pipeline.
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
The company will imminently start its third pivotal trial of PF-08634404.
The company ditches lorigerlimab in prostate cancer.
